inarigivir soproxil + tenofovir alafenamide

This drug is a **combination** of **inarigivir soproxil** and **tenofovir alafenamide**, developed primarily as an oral treatment for **chronic hepatitis B virus (HBV) infection**. Inarigivir soproxil is an immunomodulatory small molecule prodrug and a retinoic acid-inducible gene I (RIG-I) agonist that stimulates the intracellular innate immune response, activating RIG-I and possibly NOD2 (nucleotide-binding oligomerization domain-containing protein 2), leading to the production of interferons and antiviral cytokines[2][3][6][7]. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NRTI) that directly inhibits HBV DNA polymerase, blocking viral replication. The combination's hypothesis was to achieve both direct antiviral suppression (via tenofovir alafenamide) and immune stimulation (via inarigivir), aiming for functional HBV cure. Development of the combination was **terminated** due to safety concerns, specifically **hepatotoxicity** observed in trials involving inarigivir[3].

Other names

inarigivir + TAF